UPDATE: AVROBIO, Inc. (AVRO) IPO Opens 54% Higher

(Updated - June 22, 2018 9:22 AM EDT)

(Update corrects company name in headline)

Today's IPO for AVROBIO, Inc. (NASDAQ: AVRO) opened for trading at $29.25 after pricing 5,247,958 shares of common stock at a public offering price of $19.00 per share.

In addition, the Company has granted the underwriters a 30-day option to purchase up to 787,193 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions.

Morgan Stanley, Cowen and Wells Fargo Securities are acting as joint book-running managers for the offering, and Wedbush PacGrow is acting as co-manager for the offering.

AVROBIO, Inc. is a Phase 2 clinical stage gene therapy company focused on developing potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. AVROBIO is initially targeting Fabry disease, Gaucher disease, Pompe disease and cystinosis with its ex vivo gene therapy approach. AVROBIO is headquartered in Cambridge, MA and has offices in Toronto, ON.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Viking Holdings (VIK) Announces 44M Share IPO at $21-$25/sh
• Wells Fargo Upgrades Neurocrine Bio. (NBIX) to Overweight 'as the Company is Knocking on the Doors of the Large-Cap Club'
• BeiGene, Ltd. (BGNE) PT Raised to $236 at TD Cowen